Dexcom director granted 6,331 RSUs

FOLETTA MARK G reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

FOLETTA MARK G reported acquisition or exercise transactions in this Form 4 filing.

Dexcom director Mark G. Foletta received a grant of 6,331 restricted stock units (RSUs) of Dexcom common stock. The award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom's 2027 Annual Meeting of Stockholders. Each RSU represents a contingent right to receive one share of common stock upon settlement. After the grant, Foletta holds 6,331 shares directly and 56,852 shares indirectly through The Foletta Family Trust DTD 1/30/2015, where he serves as trustee.

Insider Trade Summary

Grant/Award: 6,331 shares

Grant/Award 2 txns

Insider FOLETTA MARK G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,331	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,331 shares (Direct); Common Stock — 56,852 shares (Indirect, by Trust)

Footnotes (2)

F1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
F2. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

Key Figures

RSUs granted: 6,331 units Grant price: $0.00 per share Direct holdings after grant: 6,331 shares +2 more

5 metrics

RSUs granted 6,331 units Restricted stock units of Dexcom common stock granted May 28, 2026

Grant price $0.00 per share Compensation-related RSU award, not an open-market purchase

Direct holdings after grant 6,331 shares Common stock held directly by Mark G. Foletta following RSU grant

Indirect trust holdings 56,852 shares Common stock held by The Foletta Family Trust DTD 1/30/2015

Grant date May 28, 2026 Date the RSU award was granted

Key Terms

restricted stock unit (RSU), grant, award, or other acquisition, indirect ownership, Annual Meeting of Stockholders

4 terms

restricted stock unit (RSU) financial

"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share..."

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

indirect ownership financial

"direct_or_indirect: I, ownership_type: indirect, nature_of_ownership: by Trust"

Annual Meeting of Stockholders financial

"will vest on the earlier of the one year anniversary... or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dexcom (DXCM) director Mark G. Foletta report in this Form 4?

Mark G. Foletta reported receiving a grant of 6,331 restricted stock units of Dexcom common stock. The filing also shows his existing indirect holdings of 56,852 shares held by The Foletta Family Trust, where he serves as trustee.

How many Dexcom (DXCM) RSUs were granted to Mark G. Foletta?

Mark G. Foletta was granted 6,331 restricted stock units of Dexcom common stock. These RSUs are compensation-related and carry an initial price per share of $0.00, reflecting that no cash purchase was required for the award.

When do Mark G. Foletta’s Dexcom (DXCM) RSUs vest?

The 6,331 RSUs granted to Mark G. Foletta vest 100% on the earlier of one year after the May 28, 2026 grant date or Dexcom’s 2027 Annual Meeting of Stockholders. Vesting must occur before any shares are delivered upon settlement.

What does each RSU represent in Mark G. Foletta’s Dexcom (DXCM) grant?

Each restricted stock unit represents a contingent right to receive one share of Dexcom common stock upon settlement. The units do not deliver shares immediately; actual stock is received only after the vesting conditions are satisfied and the award is settled.

How many Dexcom (DXCM) shares does Mark G. Foletta hold indirectly?

Mark G. Foletta is shown as indirectly holding 56,852 Dexcom common shares. These shares are held by The Foletta Family Trust DTD 1/30/2015, with Foletta serving as trustee, meaning the position is reported as indirect ownership in the Form 4.

Is Mark G. Foletta’s Dexcom (DXCM) RSU grant an open-market purchase?

No, the RSU grant is not an open-market purchase. It is reported under transaction code A as a grant or award, with a price per share of $0.00, indicating it is a compensation-related equity award rather than a bought position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/01/2026 - 05:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOLETTA MARK G

(Last)

(First)

(Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2026		A		6,331⁽¹⁾	A	$0	6,331	D
Common Stock								56,852	I	by Trust⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

2. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR